2026-10-25
Roper Technologies clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 28,437 +0.91%
S&P 7,689 +1.58%
GOLD $4,136 +4.95%
BTC $80,718 +4.36%
VIX 16.61 −20.26%
latest tape · as of 02:04 UTC
The Screen · Technology · Software - Application
Roper Technologies
ROP · a US exchange · USD · Market cap $46.1B · 19,400 employees
Roper Technologies, Inc.
Not yet scored473.58 USD
Price as of 3 Nov 2026Daily close, not a live quote
Screened 2026-11-03 · the tape above runs as of 02:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price473.58 USD at the 3 Nov 2026 close
- Our value readOvervalued vs our fair value, as of 3 Nov 2026
- Our regime readMarkup, as of 4 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans heavily to calls (put/call 0.09)
- Last reviewed3 Nov 2026 (2 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: $301.50 to $460.76, base estimate $400.66 (screen dated 2026-11-03).
- Trend Markup
- Insiders insiders sold, $1,571,640, latest filing 2026-10-26
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.09, read 2026-11-05
- Ethical screen not yet scored
Price473.58 USD
Fair value400.66
Ethical score87.9/100
Value readOvervaluedas of 3 Nov 2026
Our investment reviews on this name
2026-10-17Read Markup382.45+23.8% to today ✓Distribution gives way to Markup first Markup read since August
2026-09-11Read Distribution390.35+21.3% to today Markup gives way to Distribution first Distribution read since July
2026-08-11Read Markup394.53+20.0% to today ✓Distribution gives way to Markup after a 19% rise in 6 weeks
2026-07-02Read Distribution332.18+42.6% to today First review on file: Distribution with deal news in the headlines
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markup label.
Roper Technologies holds its Markup at $473.58. The statistical read favours the buyers, held for 6 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the buyers, held for 6 days |
| Price at the screen | $473.58 |
| Valuation | 18.46 trailing · 18.99 forward price to earnings |
| Values screen | Not scored · score 87.9 |
| Beta | 0.75 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 27.04% | Below 33% | Interest-bearing debt is just 27.0% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 2.30% | Below 33% | Cash held in interest-bearing accounts and securities is 2.3% of assets, under the one-third limit. | Pass |
| Receivables | 3.76% | Below 49% | Money owed to the company is 3.8% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Roper Technologies clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Roper Technologies clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 27%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 3 Nov 2026: it trades above our $400.66 fair value estimate, narrow competitive moat, 7.60% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-03 screen. The gold marker is the market price at the same screen. The price runs 18.2% above the base estimate.
Third-party analyst targets: 14 covering, consensus Buy. The average target sits +0% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & ProjectionsWhere our models see it going: fair-value estimate $400.66, with a range of $301.50 to $460.76, dated to the 2026-11-03 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it gives us pause
At 19.0x forward earnings, the price already runs ahead of the business. It trades 18% above our $400.66 fair value, so you would be buying at a premium, not a discount. The narrow moat is real, but quality alone does not make an expensive price cheap.
| Forward P/E | 19.0xexpensive even after accounting for its growth |
| Trailing P/E | 18.5xreasonably valued |
| EPS, trailing | 25.27 |
| EPS, forward | 24.57 |
| Revenue growth | +7.6%slow but positive growth |
| Profit margin | 30.7%highly profitable on every dollar of sales |
| Return on equity | 13.2%a solid return on shareholder capital |
| FCF yield | 5.28% |
| Dividend yield | 1.14% |
| Debt to equity | 0.51moderate, manageable leverage |
| Current ratio | 0.43below 1: short-term bills exceed liquid assets |
| Beta | 0.75steadier than the market |
| Short interest, float | 0.06% |
| 52-week range | 305.96 - 470.00 |
| Moat | NARROW |
| Market cap | $46.1B |
| Employees | 19,400 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeROP trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-29
Markup $438.14
+14.6% Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.6% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (16 analysts) rates it buy, with a mean price target of $454.
2026-10-22
Markup $382.45
+0.0% Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (16 analysts) rates it buy, with a mean price target of $454. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21
Markup $382.45
+0.0% Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (16 analysts) rates it buy, with a mean price target of $454. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20
Markup $382.45
+0.0% Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (16 analysts) rates it buy, with a mean price target of $454. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19
Markup $382.45
+0.0% Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (16 analysts) rates it buy, with a mean price target of $454. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18
Markup $382.45
+0.0% Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (16 analysts) rates it buy, with a mean price target of $454. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17
Markup · changed $382.45
+0.0% Entry 10
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (16 analysts) rates it buy, with a mean price target of $454. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16
Distribution $382.45
+5.0% Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 5.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (16 analysts) rates it buy, with a mean price target of $454. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15
Distribution $364.09
+0.0% Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (16 analysts) rates it buy, with a mean price target of $454. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14
Distribution $364.09
+2.9% Entry 7
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 2.9% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (16 analysts) rates it buy, with a mean price target of $454.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Roche Holding (SWX:ROP) Could Be 55% Undervalued Following Its Global BAP1 Test Launch Yahoo Finance · 7d ago
- Did Earnings Beat Just Shift Roper Technologies (ROP) Investment Narrative? Yahoo Finance · 9d ago
- Roper Technologies (ROP), What Is Behind The Fresh Attention? Yahoo Finance · 9d ago
- Roper Technologies: 3 Key Takeaways for Long-Term Investors Yahoo Finance · 9d ago
- Top Analyst Reports for Intel, Novartis & Itau Unibanco Yahoo Finance · 9d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
PAYXPaychex
WDAYWorkday, Inc.
ZMZoom Communications Inc
ADSKAutodesk
TEAMAtlassian Corp
MSTRStrategy Inc
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-26 | Stipancich John K | EVP, GC, Sec | S - Sale+OE | 3,500 | $1,571,640 |
| 2026-10-23 | Conley Jason | EVP, CFO | S - Sale+OE | 12,000 | $5,226,354 |
| 2026-05-20 | ESTEVES IRENE M | Director | 1,191 | · | |
| 2026-05-20 | JOYCE THOMAS PATRICK JR | Director | 1,191 | · | |
| 2026-03-16 | ARCHAMBEAU SHELLYE L | Director | 92 | · | |
| 2026-03-16 | ESTEVES IRENE M | Director | 85 | · | |
| 2026-03-16 | JOYCE THOMAS PATRICK JR | Director | 85 | · | |
| 2026-03-16 | WALLMAN RICHARD F. | Director | 92 | · | |
| 2026-03-10 | CROSS BRANDON L | Officer | 1,202 | · | |
| 2026-02-06 | JOYCE THOMAS PATRICK JR | Director | 1,400 | $501,844 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-09-25 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-09-25 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-09-25 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-09-18 | Kevin Hern | Republican | buy | 15K–50K |
| 2026-09-18 | Kevin Hern | Republican | buy | 15K–50K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $328.80 | +1.6% | · | $1,016 | +1.6% |
| 2 months | $343.15 | -2.6% | · | $974 | -2.6% |
| 3 months | $345.90 | -3.4% | $0.91 | $969 | -3.1% |
| 6 months | $443.80 | -24.7% | $1.82 | $757 | -24.3% |
| 1 year | $567.79 | -41.2% | $3.47 | $595 | -40.5% |
| 2 years | $549.05 | -39.2% | $6.62 | $621 | -37.9% |
| 3 years | $443.25 | -24.6% | $9.49 | $775 | -22.5% |
| 5 years | $445.45 | -25.0% | $14.46 | $782 | -21.8% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever ROP does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.